Try

SPRINGWORKS THERAPEUTICS, INC.

SWTXUnited States

23 filed reports · 289 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$192MFY2024 · to Dec 31, 2024+3,417% from $5.45M10-K$49.1MQ1 FY2025 · to Mar 31, 2025+134% from $21M10-Q
Net income-$258MFY2024 · to Dec 31, 2024a year earlier: -$325M10-K-$83.2MQ1 FY2025 · to Mar 31, 2025a year earlier: -$87.4M10-Q
Operating income-$278MFY2024 · to Dec 31, 2024a year earlier: -$343M10-K-$80.5MQ1 FY2025 · to Mar 31, 2025a year earlier: -$93.9M10-Q

Filed reports

23 reports · Sep 2019 to Mar 2025

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR171,845Sep 2019 to Mar 2025
Annual · 10-KSEC EDGAR61,844Dec 2019 to Dec 2024

Documents

PeriodTypePeriod endPublishedFactsSource
FY2025 Q110-QMar 31, 2025May 9, 2025259Open
FY202410-KDec 31, 2024Feb 20, 2025616Open
FY2024 Q310-QSep 30, 2024Nov 12, 2024148Open
FY2024 Q210-QJun 30, 2024Aug 7, 2024140Open
FY2024 Q110-QMar 31, 2024May 2, 202498Open
FY202310-KDec 31, 2023Feb 27, 2024301Open
FY2023 Q310-QSep 30, 2023Nov 2, 2023100Open
FY2023 Q210-QJun 30, 2023Aug 2, 202395Open
FY2023 Q110-QMar 31, 2023May 3, 2023108Open
FY202210-KDec 31, 2022Feb 28, 2023304Open
FY2022 Q310-QSep 30, 2022Nov 3, 2022103Open
FY2022 Q210-QJun 30, 2022Aug 4, 202293Open

Financial data

289 concepts · 3,689 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial278 concepts · 3,636 facts · Dec 2017 to Mar 2025

  • Cash cash equivalents restricted cash and restricted cash equivalents36 · Dec 2017 to Mar 2025
  • Operating income loss36 · Mar 2018 to Mar 2025
  • Stockholders equity (US GAAP)35 · Dec 2017 to Mar 2025
  • Net income loss34 · Sep 2018 to Mar 2025
  • Nonoperating income expense34 · Sep 2018 to Mar 2025
  • Research and development expense34 · Sep 2018 to Mar 2025
  • Antidilutive securities excluded from computation of earnings per share amount33 · Dec 2018 to Mar 2025
  • Increase decrease in accounts payable33 · Dec 2018 to Mar 2025
  • Increase decrease in accrued liabilities33 · Dec 2018 to Mar 2025
  • Increase decrease in other current assets33 · Dec 2018 to Mar 2025
  • Increase decrease in prepaid deferred expense and other assets33 · Dec 2018 to Mar 2025
  • Net cash provided by used in financing activities33 · Dec 2018 to Mar 2025
  • Net cash provided by used in investing activities33 · Dec 2018 to Mar 2025
  • Net cash provided by used in operating activities33 · Dec 2018 to Mar 2025
  • Payments to acquire property plant and equipment33 · Dec 2018 to Mar 2025
  • Share based compensation33 · Dec 2018 to Mar 2025
  • Common stock par or stated value per share32 · Dec 2018 to Mar 2025
  • Comprehensive income net of tax32 · Dec 2018 to Mar 2025
  • Investment income net32 · Dec 2018 to Mar 2025
  • Accounts payable current31 · Dec 2018 to Mar 2025
  • Accrued liabilities current31 · Dec 2018 to Mar 2025
  • Additional paid in capital31 · Dec 2018 to Mar 2025
  • Assets31 · Dec 2018 to Mar 2025
  • Assets current31 · Dec 2018 to Mar 2025

Segment10 concepts · 50 facts · Dec 2022 to Mar 2025

  • Commercial Expenses5 · Dec 2022 to Mar 2025
  • Cost of goods and services sold (US GAAP)5 · Dec 2022 to Mar 2025
  • Costs and expenses5 · Dec 2022 to Mar 2025
  • General and administrative expense (US GAAP)5 · Dec 2022 to Mar 2025
  • Income loss from equity method investments5 · Dec 2022 to Mar 2025
  • Investment income net5 · Dec 2022 to Mar 2025
  • Medical Expenses5 · Dec 2022 to Mar 2025
  • Net income loss5 · Dec 2022 to Mar 2025
  • Research and development expense5 · Dec 2022 to Mar 2025
  • Revenue5 · Dec 2022 to Mar 2025

Product1 concept · 3 facts · Dec 2023 to Mar 2025

  • Revenue3 · Dec 2023 to Mar 2025

Segments

53 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 50 facts

  • Developing And Commercializing Life Changing Medicines50 · Dec 2022 to Mar 2025

Product or service1 member · 3 facts

  • OGSIVEO3 · Dec 2023 to Mar 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of SPRINGWORKS THERAPEUTICS, INC. (SWTX) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.

SPRINGWORKS THERAPEUTICS, INC. (SWTX): FY2024 revenue $192M · FactIQ